Region — International. Neutral scientific reference — not offered for sale here.
Cart · 0
Set region
Vallydia
ExploreShopToolsJournalTrust
Explore  /  N-Acetyl Selank (and N-Acetyl Selank Amidate)
Research reference — not for sale

N-Acetyl Selank (and N-Acetyl Selank Amidate)

D
lead outcome
Human clinical evidence for the modified…
grades vary by outcome ↓
Peptide
also called — N-Acetyl Selank · N-Acetyl Selank Amidate · NA-Selank · NA-Selank Amidate · acetylated (and acetylated + C-amidated) tuftsin (TP-7) analogs · INCI: none
anxiolytic (derivative — research context)neuro / cognitive(parent tuftsin heritage:) immunomodulatory

Reference entry — not sold here. A doubly-modified Selank analog. The stability mechanism is real; the comparative "stronger than Selank" benefit is unproven, and the parent's clinical and safety record does not transfer to it. No dosing published here.

In brief

N-Acetyl Selank Amidate is Selank with two chemical modifications — an acetyl group added to the N-terminus and an amide at the C-terminus — marketed as a stronger, longer-lasting version. Both modifications are genuine, well-understood ways to slow enzymatic breakdown, so the pharmacokinetic rationale is plausible. But that is chemistry, not a demonstrated benefit. The actual clinical record — the Russian anxiety trials showing benzodiazepine-like efficacy without sedation — is on unmodified Selank, not on this molecule, and there are no head-to-head human studies showing the modified form does more. It is approved nowhere. Treat the "upgraded Selank" claim as an inference, not a finding.

Legal standing, by region
European Union
Not approved

Not approved; not eligible for magistral/officinal compounding (no Ph. Eur. monograph). Parent Selank is likewise unapproved in the EU.

United States
Not FDA-approved

Not FDA-approved. Sold research-use-only. The modified form is a distinct molecule from the Selank in the ongoing FDA peptide-compounding review.

International
Approved nowhere

No jurisdiction approves the modified form. Parent Selank is approved only in Russia/CIS.

Evidence, by outcome
How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade
Human clinical evidence for the modified form specifically
This is the crux: the parent's approved-in-Russia standing gets read across to a derivative that has no comparable trial base of its own.
Essentially none. The clinical record — the Russian generalized-anxiety trials versus benzodiazepines — is on unmodified Selank, not on the N-acetyl amidate. · Not established for this molecule
D
Increased metabolic stability / duration (mechanism)
A reasonable mechanism is not an outcome. "More stable at both ends" is chemistry, not a demonstrated human benefit — and modifying both termini can also change receptor interaction, not only half-life.
N-terminal acetylation and C-terminal amidation are both standard, well-understood ways to slow exopeptidase cleavage at each end of a peptide; plausible on general peptide chemistry · Plausible pharmacokinetic rationale
C
Anxiolytic / nootropic effect (the marketed use)
Sold as a stronger, longer-acting Selank. The comparative claim has no head-to-head human evidence behind it.
Extrapolated from parent Selank plus anecdote; no direct trials on this form · Suggestive at best
D
Safety
Parent Selank's notably clean profile (no sedation/tolerance/dependence) does not automatically transfer to a doubly-modified molecule.
No dedicated human safety data for the modified form · Unknown
—
Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for N-Acetyl Selank (and N-Acetyl Selank Amidate) changes - nothing else.

One ingredient, one purpose. No marketing, no sharing. Unsubscribe anytime. See our privacy policy.

The honest part

Same trap as N-Acetyl Semax: the parent is a real, approved-in-Russia drug with actual trials, and that record gets borrowed to sell a modified molecule that has essentially none of its own. Modifying both termini can change more than half-life — it can alter how the peptide engages its targets — so the derivative is not simply "Selank that lasts longer." Credit the parent; do not let its grade transfer.

Not the same as its namesake

N-Acetyl Selank Amidate is NOT the same molecule as Selank and is NOT graded as equivalent to it. The parent's evidence does not transfer to this derivative. This is a separate register entry precisely to avoid outcome substitution — do not treat a Selank grade as applying to the modified form.

Identity

Two related modified forms of Selank are sold in research channels, and this entry covers both. Selank itself is a synthetic heptapeptide — the immune tetrapeptide tuftsin (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tail for stability. The derivatives cap one or both ends:

  • N-Acetyl Selank — an acetyl group on the N-terminus only.
  • N-Acetyl Selank Amidate — an acetyl group on the N-terminus and an amide on the C-terminus (both ends capped).

Both modifications are standard moves to block the exopeptidases that chew peptides inward from each end, and the intent in each case is a molecule that survives longer in the body. They are not identical to each other, and neither is identical to plain Selank — the amidate form carries one more modification than the acetyl-only form, which puts it a further step from the parent. Where this entry needs a single canonical reference it uses the doubly-modified amidate; the honest points below apply to both.

The claim, and what actually backs it

As with every "N-acetyl" peptide sold in research channels, the pitch is comparative: stronger, longer-lasting, more potent than regular Selank. The longer-lasting half has a real basis — capping both termini genuinely slows enzymatic degradation, which is settled chemistry.

The stronger / does-more-in-a-person half does not. There are no head-to-head human trials comparing this modified form to Selank on anxiety, cognition or any other outcome. The clinical record people point to — the Russian trials showing Selank relieves generalized anxiety without the sedation or dependence of benzodiazepines — was done on unmodified Selank. Reading that record onto the acetyl-amidate is an assumption, and exactly the kind this register flags: the parent's evidence is being borrowed to sell a derivative that has not earned it. There is a further subtlety — modifying both termini can change how a peptide engages its targets, not just how long it lasts, so "the same drug but better" is not a safe assumption even in principle.

Mechanism (as proposed)

Like its parent, N-Acetyl Selank Amidate is proposed to act through Selank's multi-target profile: allosteric modulation of GABA-A receptors without the benzodiazepine site (anxiolysis without sedation or dependence), enkephalinase inhibition, serotonin modulation, hippocampal BDNF upregulation, and the tuftsin-derived immune arm. The two terminal caps are proposed to extend duration by resisting exopeptidase cleavage. This is a plausible pharmacokinetic story — but a mechanism is not an outcome, and only the stability half of it has support.

Sources — 2 cited
01(Parent compound: Institute of Molecular Genetics, RAS — Selank development, Myasoedov et al.; Russian registration as an anxiolytic. The acetyl-amidate analog has no comparable independent clinical literature; cite parent-Selank sources only where the claim is explicitly about the parent.)
02General peptide-chemistry references on N-terminal acetylation and C-terminal amidation as exopeptidase-resistance strategies.
Updated 2026-08-07 (Derivative with essentially no molecule-specific clinical base — grade rests on the honest gap between the parent's record and this form's absence of one.)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds
SelankC
Peptide
SemaxC
Peptide
N-Acetyl SemaxD
Peptide
Explore by goal
Neuro & cognitive →Immune & thymic →
Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International
ExploreRegisterThe Register — full indexCategoriesTrust & COAHow we gradeOpen data
ShopCosmetic peptidesJournalQuizzes
TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.